Literature DB >> 15553238

Functional analysis of SNPs variants of BCRP/ABCG2.

Chihiro Kondo1, Hiroshi Suzuki, Masaya Itoda, Shogo Ozawa, Jun-ichi Sawada, Daisuke Kobayashi, Ichiro Ieiri, Kazunori Mine, Kenji Ohtsubo, Yuichi Sugiyama.   

Abstract

PURPOSE: The aim of the current study was to identify the effect of single nucleotide polymorphisms (SNPs) in breast cancer resistance protein (BCRP/ABCG2) on its localization, expression level, and transport activity.
METHODS: The cellular localization was identified using the wild type and seven different SNP variants of BCRP (V12M, Q141K, A149P, R163K, Q166E, P269S, and S441N BCRP) after transfection of their cDNAs in plasmid vector to LLC-PK1 cells. Their expression levels and transport activities were determined using the membrane vesicles from HEK293 cells infected with the recombinant adenoviruses containing these kinds of BCRP cDNAs.
RESULTS: Wild type and six different SNP variants of BCRP other than S441N BCRP were expressed on the apical membrane, whereas S441N BCRP showed intracellular localization. The expression levels of Q141K and S441N BCRP proteins were significantly lower compared with the wild type and the other five variants. Furthermore, the transport activity of E1S, DHEAS, MTX, and PAH normalized by the expression level of BCRP protein was almost the same for the wild type, V12M, Q141K, A149P, R163K, Q166E, and P269S BCRP.
CONCLUSIONS: These results suggest that Q141K SNPs may associate with a lower expression level, and S441N SNPs may affect both the expression level and cellular localization. It is possible that subjects with these polymorphisms may have lower expression level of BCRP protein and, consequently, a reduced ability to export these substrates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15553238     DOI: 10.1023/b:pham.0000045245.21637.d4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

Authors:  M de Bruin; K Miyake; T Litman; R Robey; S E Bates
Journal:  Cancer Lett       Date:  1999-11-15       Impact factor: 8.679

2.  Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.

Authors:  Kumie Kage; Satomi Tsukahara; Tomomi Sugiyama; Sakiyo Asada; Etsuko Ishikawa; Takashi Tsuruo; Yoshikazu Sugimoto
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

3.  ABCG2 transports sulfated conjugates of steroids and xenobiotics.

Authors:  Michiko Suzuki; Hiroshi Suzuki; Yoshikazu Sugimoto; Yuichi Sugiyama
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

4.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

Authors:  Yasuo Imai; Minoru Nakane; Kumie Kage; Satomi Tsukahara; Etsuko Ishikawa; Takashi Tsuruo; Yoshio Miki; Yoshikazu Sugimoto
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

6.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.

Authors:  K Nakatomi; M Yoshikawa; M Oka; Y Ikegami; S Hayasaka; K Sano; K Shiozawa; S Kawabata; H Soda; T Ishikawa; S Tanabe; S Kohno
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

Review 7.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

Authors:  T Litman; T E Druley; W D Stein; S E Bates
Journal:  Cell Mol Life Sci       Date:  2001-06       Impact factor: 9.261

8.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

Authors:  J W Jonker; J W Smit; R F Brinkhuis; M Maliepaard; J H Beijnen; J H Schellens; A H Schinkel
Journal:  J Natl Cancer Inst       Date:  2000-10-18       Impact factor: 13.506

9.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.

Authors:  Erin L Volk; Erasmus Schneider
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

10.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

View more
  74 in total

1.  Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.

Authors:  Prateek Bhatia; Michel Bernier; Mitesh Sanghvi; Ruin Moaddel; Roland Schwarting; Anuradha Ramamoorthy; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-03-08       Impact factor: 1.908

2.  Predictable difficulty or difficulty to predict.

Authors:  Tamás Arányi; Krisztina Fülöp; Orsolya Symmons; Viola Pomozi; András Váradi
Journal:  Protein Sci       Date:  2011-01       Impact factor: 6.725

3.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 4.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

Review 5.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

6.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

7.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

8.  Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

Authors:  Tomoka Furukawa; Kanako Wakabayashi; Ai Tamura; Hiroshi Nakagawa; Yoshihiro Morishima; Yoichi Osawa; Toshihisa Ishikawa
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

Review 9.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

10.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.